Search alternatives:
significantly predicted » significantly reduced (Expand Search), significantly reduce (Expand Search), significant predictor (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
predicted decrease » predicted secreted (Expand Search), reported decrease (Expand Search)
significantly predicted » significantly reduced (Expand Search), significantly reduce (Expand Search), significant predictor (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
predicted decrease » predicted secreted (Expand Search), reported decrease (Expand Search)
-
341
-
342
-
343
Baseline characteristics and potential independent risk factors for mortality of SFTS.
Published 2025Subjects: -
344
Kinetics of coagulation parameters between the survivors and non-survivors during hospitalization.
Published 2025Subjects: -
345
Restricted cubic spline models depicting the relationship between APTT and mortality risk in SFTS.
Published 2025Subjects: -
346
-
347
-
348
Kaplan-Meier survival analysis curves according to the APTT levels between four groups.
Published 2025Subjects: -
349
Dynamic profile of coagulation parameters between survivors and non-survivors in patients with SFTS.
Published 2025Subjects: -
350
Multivariate logistic regression analysis on the risk factors associated with prolonged APTT.
Published 2025Subjects: -
351
Characteristics and outcomes of participants categorized by serum APTT on admission.
Published 2025Subjects: -
352
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
353
-
354
-
355
Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
356
Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
357
-
358
-
359
-
360